mTORC1 is a validated therapeutic target for renal cell carcinoma (RCC). Here, analysis of Tsc1-deficient (mTORC1 hyperactivation) mice uncovered a FoxO-dependent negative feedback circuit constraining mTORC1-mediated renal tumorigenesis. We document robust FoxO activation in Tsc1-deficient benign polycystic kidneys and FoxO extinction on progression to murine renal tumors; murine renal tumor progression on genetic deletion of both Tsc1 and FoxOs; and downregulated FoxO expression in most human renal clear cell and papillary carcinomas, yet continued expression in less aggressive RCCs and benign renal tumor subtypes. Mechanistically, integrated analyses revealed that FoxO-mediated block operates via suppression of Myc through upregulation of the Myc antagonists, Mxi1-SRa and mir-145, establishing a FoxO-Mxi1-SRa/mir-145 axis as a major progression block in renal tumor development.
INTRODUCTION
The mammalian target of rapamycin complex 1 (mTORC1) serves as the key regulator of protein synthesis and cell growth via phosphorylation of a variety of downstream targets, including S6 Kinase and 4E-BP1 (Ma and Blenis, 2009; Wullschleger et al., 2006) , and plays a critical role in the regulation of cell growth, angiogenesis, and metabolism in many human cancers, including renal cell carcinoma (RCC) (Guertin and Sabatini, 2006, 2007; Hanna et al., 2008; Inoki et al., 2005) . RCC comprises $3% of all adult malignancies, ranks among the top 10 cancers in the United States, and continues to show modest responses to most conventional cancer treatments (Linehan and Zbar, 2004; Rini et al., 2009 ). mTORC1 hyperactivation is observed in the majority of human RCC samples (Pantuck et al., 2007; Robb et al., 2007) and has emerged as a therapeutic target for RCC after several clinical trials establishing clinical benefit of mTORC1 inhibitors (Atkins et al., 2004; Hudes et al., 2007; Motzer et al., 2008) . Given the clinical relevance of the mTORC1 target in RCC, an understanding of mTORC1's complex signaling circuitry in vivo may inform its role in RCC pathogenesis and guide further drug development efforts.
Significance
The clinical response of RCC to mTORC1 inhibition has been modest. The clinical application of mTORC1 inhibitors may be improved by the development of mTORC1-directed mouse models of RCC and by illumination of the mTORC1 activation network in RCC pathogenesis. This study reports the engineering of a highly penetrant model of renal adenoma/carcinoma and identification of a FoxO-Myc network as integral regulators of renal tumorigenesis in mice and humans. Illumination of this circuit may provide strategies to understand the variable clinical response to mTORC1 inhibition in RCC patients and motivate the development of combination treatment by mTORC1 inhibitors and agents reactivating FoxO or targeting Myc in human RCC.
Increasing knowledge of mTORC1 signaling has demonstrated that mTORC1 acts both downstream and upstream of PI3K-AKT signaling. Whereas activated PI3K-AKT signaling promotes mTORC1 signaling through AKT-mediated phosphorylation of both TSC2 and PRAS40, mTORC1 hyperactivation also leads to feedback shutoff of PI3K/AKT signaling via a S6 Kinasedependent downregulation of upstream activators of PI3K including the PDGF receptor and IRS-1 (Bhaskar and Hay, 2007; Guertin and Sabatini, 2007; Hay and Sonenberg, 2004; Manning, 2004; Um et al., 2006) . A major upstream regulator of mTORC1 is the TSC1-TSC2 complex, which functions to inhibit the mTORC1 activity via stimulation of GTP hydrolysis and inactivation of small GTPase Rheb, an activator of mTORC1 (Huang and Manning, 2008; Kwiatkowski and Manning, 2005; Li et al., 2004) . These observations hold important therapeutic implications in that, in specific genotypic contexts, mTORC1 inhibitor treatment alone might enhance tumorigenesis in mTORC1 hyperactivation-driven tumors by stimulating PI3K-AKT-dependent survival and cell cycle entry, thereby prompting calls for combination therapeutic regimens in the clinic (Shaw and Cantley, 2006) . Along these lines, the rational design and effective implementation of such combinations requires a more definitive understanding of the key downstream effector(s) of AKT that mediate this mTORC1-directed negative feedback circuit.
The PI3K-AKT axis is activated in virtually all human cancers (Cully et al., 2006; Luo et al., 2003; Salmena et al., 2008; Samuels et al., 2004) . The wide range of tumorigenic phenotypes mediated by PI3K-AKT signaling is consistent with the existence of diverse downstream effectors including TSC1-TSC2 complex, FoxOs, GSK3 and MDM2. These effectors operate in a highly context-specific manner, i.e., effectors are coordinately or differentially used in conferring neoplastic phenotypes in distinct cell lineages and genotypes (Manning and Cantley, 2007) . The mammalian FoxO transcription factors-FoxO1, FoxO3, FoxO4-function in the nucleus to direct transcription of specific gene targets governing cellular survival, proliferation, metabolism, differentiation, and oxidative defense. Activation of PI3K by extracellular growth factors leads to AKT-mediated phosphorylation of FoxO1, FoxO3, and FoxO4, resulting in their sequestration in the cytoplasm such that they are unable to regulate their gene targets (Accili and Arden, 2004; Greer and Brunet, 2005) . The role and essentiality of the FoxOs in tumor suppression in vivo has received formal proof from murine genetic studies wherein broad somatic deletion of all three FoxOs was shown to engender a cancer-prone condition dominated by hemangiomas and lymphomas (Paik et al., 2007) . However, the highly context and cell-lineage specific functions of FoxO as revealed from this study also highlights the necessity to fully characterize its tumor suppression function in other cell types and tissue contexts. We studied FoxO tumor suppression function in the context of mTORC1-mediated renal tumorigenesis.
RESULTS
FoxOs Are Activated in Tsc1-Deficient Polycystic Kidneys, but Lost in Tsc1-Deficient Renal Adenomas and Carcinomas To better understand the molecular and biological role of mTORC1 hyperactivation in renal cancer development, we assessed the impact of homozygous deletion of Tsc1 conditional knockout (KO) allele (Tsc1 L ) (Kwiatkowski et al., 2002) using the Rosa26-CreERT2 knock-in deletor allele that enables tamoxifen-inducible Cre-mediated excision of conditional knockout alleles in most tissues, including kidneys (Vooijs et al., 2001) .
resulted in efficient deletion of Tsc1 in the kidney (see Figures  S1A and S1B available online) as well as other organs (data not shown). As recently reported (Gan et al., 2008) , somatic deletion of Tsc1 in adult mice (Tsc1 L/L , Rosa26-CreERT2, hereafter referred to as ''Tsc1 KO'') led to the development of polycystic kidney disease (Figures 1Aa-1Ac ), as well as severe hematopoietic defects (data not shown) compared with littermate ''Tsc1 wild-type (WT)'' control mice (Tsc1 L/L or Tsc1 +/+ , Rosa26-CreERT2 mice treated with tamoxifen). All Tsc1 KO mice developed severe renal and bone marrow failure and died within 7 weeks (Gan et al., 2008) . Notably, all Tsc1 KO mice developed bilateral polycystic kidneys with >10-fold weights relative to littermate controls ( Figure 1Ac ) and significantly dilated renal tubules on histopathological analysis (Figures 1Aa and 1Ab) , which is consistent with the documented connection between tuberous sclerosis and polycystic kidney disease (Cai and Walker, 2006) .
The Tsc1 KO polycystic kidneys exhibited increased phospho-S6 staining compared with WT kidneys ( Figure S1C ), and rapamycin treatment of Tsc1 KO mice resulted in full rescue of the polycystic kidney defect (data not shown), strongly suggesting that mTORC1 hyperactivation upon loss of Tsc1 drives the polycystic kidney phenotype in the Tsc1 KO model. Given the lethality of the Tsc1 KO mice, we also established a large cohort of Tsc1 L/+ , Rosa26-CreERT2 mice (hereafter referred to as ''Tsc1 +/À '') for long-term tumor studies. Consistent with previous reports from mice heterozygous for germ line Tsc1 null allele (Kobayashi et al., 2001; Kwiatkowski et al., 2002) , our conditional Tsc1 +/À model showed renal adenomas and/or carcinomas after long latency (>14 months) (Figures 1Ad and 2B ). These renal adenomas and carcinomas demonstrated loss of heterozygosity (LOH) for the remaining Tsc1 allele (six of six samples examined; data not shown) as well as increased phospho-S6 staining indicative of mTORC1 hyperactivation ( Figure 1C ). The long latency required for the development of Tsc1-deficient renal carcinomas prompted us to consider that this model could prove useful in the identification of physiologically relevant checkpoint pathways activated in Tsc1 KO premalignant polycystic kidneys and enable the validation of such checkpoints through a detailed comparative analysis of activation status of TSC-mTORC1-related signaling surrogates in Tsc1-deficient polycystic lesions versus tumor samples. These comparative analyses revealed strong FoxO1 and FoxO3 staining with predominant nuclear localization ( Figure 1B ), a pattern consistent with strong FoxO activation in Tsc1 KO polycystic kidneys relative to WT kidney samples.
In line with these tissue findings, Tsc1 and Tsc2 KO MEFs exhibited decreased FoxO1/3 phosphorylation compared with WT MEFs ( Figure S1D ) and, accordingly, showed predominant FoxO1/3 nuclear localization under both serum starvation and stimulation conditions ( Figure S1E ). This profile corresponds well with the anticipated constitutively high mTORC1 activity and dramatically reduced AKT phosphorylation in Tsc-deficient MEFs ( Figure S1D ). On this basis, we considered a model in which the regulation of FoxO activity might play a critical effector role in the mTORC1-AKT negative feedback circuit and that FoxO extinction would promote tumorigenesis. In line with this hypothesis, we observed marked reduction/loss of both FoxO1 and FoxO3 staining in all Tsc1 KO renal adenoma/carcinoma samples examined (10 of 10 bilateral kidneys, each with multiple renal adenomas/carcinomas) compared with surrounding nonmalignant cells ( Figure 1C ). Furthermore, western blotting analysis revealed significant reduction of FoxO4 protein levels in Tsc1-deficient renal tumors compared with adjacent normal kidney samples ( Figure S1F ). Together, these data are consistent with the possibility that FoxO activation participates in a feedback checkpoint functioning to restrain the renal tumorigenesis initiated by loss of Tsc1, and that subsequent loss of FoxO may be required for renal cancer development in Tsc1-deficient mice. (Figure 2A ). The decrease in survival in FoxO À/À mice relates to hemangiosarcomas and thymic lymphomas as previously reported (Paik et al., 2007) and careful inspection of the kidneys showed no evidence of renal adenoma or carcinoma (data not shown). In contrast, Tsc1 +/À FoxO À/À mice showed dramatic reduction in latency and increased penetrance of renal adenomas and carcinomas ( Figure 2B ). Notably, the penetrance and onset of FoxO 
FoxOs Are Extinguished in the Majority of Human Renal Tumor Samples
The above data from murine model systems prompted detailed examination of FoxO expression/activation status in human kidney tumor samples. RCC is the most common malignancy of the adult kidney and presents as a heterogeneous group of tumors with distinct histological features, including clear cell, papillary (including both type 1 and type 2), and chromophobe RCC as well as rarer subtypes (Lopez-Beltran et al., 2006) . Clear cell RCC (ccRCC) is the predominant subtype and accounts for up to 75% of total RCC cases (Linehan and Zbar, 2004; Rini et al., 2009) . It is generally considered that all the clear-cell tumors are carcinomas, with greater or lesser aggressiveness, and an adenoma state of clear cells is not accepted (Algaba, 2008) . Compared with more aggressive clear cell and papillary subtypes, chromophobe RCCs tend to have a benign course after surgery, provided that the tumor stage and grade are favorable at the time of surgery (Cohen and McGovern, 2005) . Benign epithelial neoplasms also occur in the kidney, including oncocytoma and metanephric adenoma, among others.
To assess FoxO expression in this spectrum of benign and aggressive kidney tumor types, FoxO1 and FoxO3 protein abundance was determined by immunohistochemistry (IHC) in a tissue microarray (TMA) that contained 21 normal kidney samples, 68 clear cell RCC, 10 papillary RCC, 8 chromophobe RCC, 5 oncocytomas, as well as several rare renal tumor subtypes. TMA-IHC analysis revealed FoxO1 and FoxO3 cytoplasmic and nuclear signal in both the proximal and distal tubular epithelium in normal kidney samples (Figures 3Aa and 3Ca ). In contrast, FoxO1 and FoxO3 signal was not detectable in the majority of clear cell and papillary RCC samples (FoxO1: 64 of 68 clear cell and 8 of 10 papillary; FoxO3: 63 of 68 clear cell and 7 of 10 papillary) ( Figures 3A-3D ). FoxO1 and FoxO3 signal was readily detected in the tumor endothelial cells, providing a positive internal staining control ( Figure S2A ; data not shown). Notably, all of the less aggressive RCCs and benign renal tumors retained FoxO1 and/or FoxO3 expression ( Figures 3A-3D ). FoxO1 nuclear signal was especially strong in oncocytoma samples ( Figure S2B ).
We also assessed phospho-S6 staining on the same TMA sample set. This analysis revealed negative to weak phospho-S6 staining in most normal kidney samples and moderate to strong phospho-S6 staining in the majority of human renal clear cell and papillary carcinomas samples (Figures 3E and 3F) , consistent with previous reports that mTORC1 hyperactivation is observed in the majority of human RCC samples (Pantuck et al., 2007; Robb et al., 2007) . Importantly, our analysis also showed negative to weak phospho-S6 staining in chromophobe RCC, oncocytoma and metanephric adenoma samples (Figures 3E and 3F) . The inverse staining pattern between FoxO1/3 and phospho-S6 from different human renal tumor types provides further support to our conclusion that FoxOs serve as a checkpoint in mTORC1-activated renal tumorigenesis.
FoxO Activation Promotes Cell Cycle Arrest and Apoptosis in Human RCC Cells
The above data prompted further examination of FoxO function in human RCC cell lines. We first examined the expression levels of FoxO1/3 and mTORC1 activation status in a panel of human RCC cell lines and the immortalized WT human kidney cells (HK2). Consistent with the data from murine renal tumors (Figure 1C) , these analyses revealed that high phosphorylation levels of S6 (surrogate of mTORC1 activation) in general correlated with low expression levels of FoxO1 and FoxO3 in these human RCC cell lines ( Figure 4A ). We then assessed the impact of FoxO reactivation in RCC4 and UMRC2 cells that harbor low FoxO1/3 expression and high mTORC1 activation. To this end, we generated RCC4 and UMRC2 cell lines with stable expression of FoxO1(TA)ERT2 or FoxO3(TA)ERT2 construct, which expressed a fusion protein consisting of FoxO(TA) (containing three Ser/Thr AKT phosphorylation sites mutated to alanine) fused to the T2-modified estrogen receptor (ERT2) moiety ( Figure S3A ). We documented that FoxO(TA)ERT2 fusion protein sequestered FoxO(TA) in the cytoplasm and that 4OHT treatment resulted in rapid translocation of FoxO(TA)ERT2 into nucleus ( Figure S3B ). We also established stable cell lines with ERT2 expression as control cell lines. (For simplicity, ERT2, FoxO1(TA)ERT2, and FoxO3(TA)ERT2 cell lines will be referred to as empty vector [EV] , FoxO1, and FoxO3 thereafter). 4OHT treatment of FoxO1 or FoxO3 RCC4 cells resulted in marked cell growth suppression compared with vehicle-treated cells or 4OHT-treated EV RCC4 cells ( Figures 4B and 4C ). Further analysis demonstrated that FoxO reactivation in RCC4 cells led to potent G1/S cell cycle arrest ( Figure 4D ) and enhanced apoptosis ( Figure 4E ). Reactivation of FoxO1/3 in UMRC2 cells resulted in similar phenotypes ( Figures S3C-S3E ). Finally, in UOK101 cells that maintain FoxO3 and FoxO1 expression, knockdown of both FoxO1 and FoxO3 led to increased cell proliferation ( Figures 4F and 4G ).
These human RCC cell line data align with our murine data, strongly supporting the view that FoxOs function as tumor suppressors in the progression to human RCC.
Myc Signaling Is the Key Downstream Effector of FoxOs in the Regulation of Renal Tumorigenesis
We next sought to determine the mechanisms by which FoxO might govern the biology of RCC cells. To this end, we conducted comparative transcriptome analysis of EV, FoxO1, or FoxO3-expressing RCC4 and UMRC2 cells at 12 hr with or without 4OHT treatment. To enrich for more proximal actions of FoxO, we selected the 12-hr time point as time course studies revealed dramatic transcriptional changes of known FoxO targets (such as Cyclin D1), yet no discernible cellular phenotypes (apoptosis and cell cycle arrest) (data not shown). We generated four transcriptome data sets: FoxO1 RCC4, FoxO3 RCC4, FoxO1 UMRC2, and FoxO3 UMRC2, and normalized these transcriptome data against 4OHT-treated EV cells that show modest 4OHT-induced transcriptional changes (Figure 5A) . As FoxO1 or FoxO3 reactivation generated comparable phenotypes, we further intersected FoxO1 and FoxO3 transcriptome data sets and focused on 503 genes exhibiting similar changes (designated as ''FoxO RCC transcriptome''; Figure 5B ; Table S1 ).
Next we conducted GSEA to identify gene sets that are enriched in FoxO RCC transcriptome. This analysis readily identified FoxO (TTGTTT_V$FOXO4_01), hypoxia (MANALO_ HYPOXIA_DN) (Manalo et al., 2005) , and E2F (V$E2F_Q6_01) gene sets in FoxO RCC transcriptome ( Figure 5C ; see Figure S4A for gene set description). Most notably, the analysis revealed a previously described Myc oncogenic signature (Bild et al., 2006) as the most significantly enriched gene set (p = 4.51 3 10 À16 ; Figure 5C and Figure S4A ). Accordingly, Myc binding motif-containing gene set (CACGTG_V$MYC_Q2) was also significantly enriched in FoxO RCC transcriptome ( Figure 5C and Figure S4A ). 2009), the involvement of Myc signaling in renal neoplasia as evidenced in genetically engineered mouse models (SchreiberAgus et al., 1998; Trudel et al., 1991) and human cell culture studies (Eilers and Eisenman, 2008; Gordan et al., 2007a; Zhang et al., 2007 ) (see Discussion). To understand how FoxO might intersect with Myc signaling, we first considered a model wherein FoxO and Myc might coregulate a common set of transcription targets through cobinding on the same promoters. In silico promoter analysis of FoxO RCC transcriptome identified 90 putative FoxO direct targets and 81 putative Myc direct targets. However, integration of these two data sets only revealed 12 common targets, which is statistically insignificant (p > 0.5) ( Figure S4B ). Furthermore, the computational analysis showed that the FoxO putative targets (TTGTTT_V$FOXO4_01) are enriched in upregulated genes of the FoxO RCC transcriptome, whereas Myc signature genes (MYC_ONCOGENIC_ SIGNATURE) are mostly enriched in downregulated genes of the FoxO RCC transcriptome ( Figure 5D ), suggesting FoxO might function to inhibit Myc activity and/or expression.
FoxOs Regulate Myc through Mxi-1 and mir-145 in RCC Cells
We and others previously showed that Mxi1 splicing variant strong repressor (Mxi1-SRa), but not Mxi1 weak repressor (Mxi1-WR), mediates antagonistic actions on Myc activity through recruitment of Sin3A-HDAC transcriptional repressor complex (Alland et al., 1997; Ayer et al., 1995; Heinzel et al., 1997; Schreiber-Agus et al., 1995) . Mxi1-SRa was identified to be a FoxO direct target in other cellular contexts (Delpuech et al., 2007 (Figures 6C and 6D ; Figure S5C ). The absence of FoxO binding elements in the Myc promoter region prompted us to consider that FoxO may regulate microRNA(s) governing Myc expression. To test this hypothesis, we examined the FoxO RCC transcriptome for enrichment of putative targets of microRNA genes, searched the microRNA promoter regions for putative FoxO binding elements (BEs), and determined whether any of these microRNAs could also target Myc via the targetScan algorithm and literature mining. This effort identified mir-145 that is known to target Myc (Sachdeva et al., 2009) (D) The distribution of putative FoxO targets (TTGTTT_V$FOXO4_01) and Mycregulated genes (MYC_ONCOGENIC_SIGNATURE) in RCC4 FoxO3 transcriptome data set. All genes were sorted according to expression changes in RCC4 FoxO3 transcriptome data set (the red curve). The frequency of either putative FoxO targets (TTGTTT_V$FOXO4_01) or Myc-regulated genes (MYC_ONCOGENIC_SIGNATURE) in a sliding window of 1,000 sorted genes was calculated. See also Figure S4 and Table S1 . upstream of mir-145 transcriptional start site ( Figure S5D ). Quantitative RT-PCR confirmed that FoxO3 activation can significantly upregulate mir-145 expression in RCC4 cells ( Figure 6E ). Conversely, knockdown of FoxO1 and FoxO3 in UOK101 cells led to decrease of mir-145 and Mxi1-SRa expression, and increase of Myc expression ( Figure 6F ). Furthermore, chromatin immunoprecipitation (ChIP) analysis documented that both ectopically expressed and endogenous FoxO1 and FoxO3 can directly bind to both FoxO BEs in mir-145 promoter region (Figure 6G ; Figure S5E ). Importantly, knockdown of mir-145 by antimir-145 ( Figure S5F ) significantly normalized Myc expression on FoxO activation ( Figure 6H ), strongly suggesting that mir-145 contributes to FoxO-mediated suppression of Myc expression in RCC cells. Consistent with recent report in other cell types (Sachdeva et al., 2009) , we found overexpression of mir-145 was sufficient to downregulate Myc expression ( Figure S5G and S5H) and inhibit cell growth in RCC4 cells ( Figure S5I ). Finally, knockdown of Mxi1-SRa, knockdown of mir-145, and overexpression of Myc, either individually or in combination, can significantly rescue the cell growth inhibition effected by FoxO activation in RCC4 cells ( Figure 6I ). Together, these data establish that FoxO inhibits both Myc activity and expression via transcriptional regulation of Mxi1-SRa and mir-145, and that Myc signaling is at least one key downstream effector of FoxO in RCC cells.
Myc/Mxi1-SRa/mir-145 Alterations in Tsc1 Renal Cancer Mouse Models and Human RCCs
The above mechanistic studies in renal cancer cell culture systems prompted further investigation of Myc signaling in vivo in the context of RCC development in mice and humans. Examination of Myc/Mxi1-SRa/mir-145 status in Tsc1 mouse models revealed that mir-145 and Mxi1-SRa expression levels were upregulated in Tsc1 KO polycystic kidneys (with FoxO activation) and downregulated in Tsc1 KO kidney tumors (with FoxO extinction) compared with Tsc1 WT kidneys ( Figure 7A ). Furthermore, although Myc expression was downregulated in Tsc1 KO polycystic kidneys compared with Tsc1 WT kidneys ( Figure 7A ), there was no obvious difference in Myc protein levels and in expression levels of Myc targets between Tsc1 KO polycystic kidneys and Tsc1 WT kidneys ( Figures 7B and 7C ). Myc expression and protein levels, and Myc target expression levels, are dramatically increased in Tsc1 KO kidney tumors compared with either Tsc1 WT kidneys or Tsc1 KO polycystic kidneys ( Figures 7A-7C ). Because mTORC1 hyperactivation is also known to promote Myc translation (West et al., 1998) , our data together suggest that, in Tsc1 KO polycystic kidneys with mTORC1 hyperactivation and FoxO activation, Myc protein level is balanced by both increased protein synthesis afforded by mTORC1 hyperactivation and decreased mRNA levels via FoxO activation. While in Tsc1 KO kidney tumors, loss of FoxO expression leads to increased Myc expression. This, together with increased protein synthesis, leads to further increased Myc protein level, which contributed to the renal tumorigenesis in Tsc1 KO mice. Examination of Myc/Mxi1-SRa/mir-145 status in human RCCs in published human RCC transcriptome data set (including 11 normal kidney samples and 59 ccRCC samples) (Beroukhim et al., 2009 ) revealed that Myc expression was significantly upregulated in ccRCCs compared with normal kidneys (Figure 7D ; p = 7.42 3 10 À9 ), correlating with aforementioned data that FoxO1/3 are extinguished in the majority of human ccRCC samples. Further computational analyses revealed that the mean expression levels of Myc signature genes (the same signature genes used in our FoxO RCC transcriptome analysis in Figure 5C ) were significantly upregulated in ccRCCs compared with normal kidneys ( Figure S6A ) (p = 4.12 3 10 À11 ) and that the expression levels of Myc positively correlated with the mean expression levels of Myc signature genes in ccRCC and normal kidney samples ( Figure 7E ; Pearson correlation coefficient: 0.61, p = 2.03 3 10 À8 ), strongly suggesting that Myc signaling is also upregulated in ccRCCs. We also performed RT-qPCR experiments to examine the expression levels of Myc, selected Myc targets (CCND2, GADD45A, LDHA, HK2, and ENO1), mir-145, and Mxi1-SRa in 12 human ccRCC and matched normal kidney samples. These experiments confirmed upregulation of Myc, CCND2, LDHA, HK2, and ENO1, but downregulation of mir-145, Mxi1-SRa, and GADD45A (Myc-repressed target) in ccRCC compared with matched normal kidney samples (Figures 7F-7H ; Figures S6B-S6F ). Together, our data strongly suggests that FoxO regulation of Myc/Mxi1-SRa/mir-145 signaling network plays a role in suppressing renal tumorigenesis in Tsc1 renal tumor mouse model and human RCCs ( Figure 7I ).
DISCUSSION
The mTORC1-mediated negative feedback regulation of PI3K-AKT (Shaw and Cantley, 2006) , cancer type-specific nature of PI3K-AKT pathway signaling in vivo, and the multiple AKT downstream effectors in cancer (Manning and Cantley, 2007) prompted us to define mTORC1 circuitry on the genetic, genomic, and biological levels in RCC pathogenesis. By using genetically defined mice and human RCC cell line models, this study establishes that FoxOs play a critical role in an mTORC1-directed negative feedback circuit in the context of renal tumorigenesis. FoxO1 and FoxO3 are robustly activated in Tsc1-deficient benign polycystic neoplasias as well as Tsc1 KO MEFs, and consistently extinguished on progression to renal adenomas and carcinomas. In addition, combined deletion of Tsc1 and FoxO1/3/4 provoked dramatic exacerbation of the renal tumor phenotypes, establishing activated FoxO signaling as a potent block in Tsc1 null renal cancer development. In elucidating the biological mechanisms by which loss of FoxO serves to promote Tsc1 null renal cancer development, we provide evidence that knockdown of FoxO in RCC cells leads to increased Myc expression and enhanced cell proliferation, supporting a model that loss of FoxO and subsequent Myc activation function to promote cell cycling at the transition from premalignant polycystic kidney epithelial cells to adenoma in Tsc1 mice. In addition, although FoxO is a key progression factor, we acknowledge that loss of FoxO (and Tsc1 LOH) may represent one of several genetic networks commandeered in the course of kidney tumorigenesis, a view consistent with lengthy renal tumor latency in our Tsc1 +/À FoxO À/À mice. Thus, this model system may serve as a foundation for identification of cooperative genetic events involved in renal tumorigenesis. The FoxO family members serve as redundant tumor suppressors in vivo, and FoxO1 and FoxO3 exert the major tumor suppressor activity (Paik et al., 2007) . Correspondingly, we observed that FoxO1 and FoxO3 are always co-extinguished in Tsc1-deficient mouse renal tumors and human renal tumors, suggesting that both FoxOs need to be eliminated to bypass In this study, we found FoxO1 and FoxO3 levels are extinguished in the majority of the aggressive subtypes of human RCC, including clear cell and papillary tumors, but maintained or robustly activated in less aggressive carcinomas (i.e., chromophobe RCC) and benign tumors. The underlying mechanisms responsible for such differential expression/activation patterns of FoxOs in different kidney tumor types are not understood currently. It is worth noting that recent oncogenomic analysis identified frequent hemizygous deletions at 13q in human clear cell RCC samples, and FoxO1 was identified as a downregulated gene in the minimal common region of the 13q deletion (Kojima et al., 2010) , suggesting that genomic alteration might be at least a contributing mechanism for the loss of FoxO1 staining in our analysis. We speculate that other mechanisms operating on the epigenetic and posttranslational levels might be also involved in effecting extinction of FoxO expression/activity in these RCC samples.
Our integrated transcriptomic, computational, and functional studies identified Myc-Mxi1 signaling as the key downstream effector of FoxOs in the regulation of renal cancer cell proliferation. This finding is particularly intriguing in light of our previous work showing that deletion of Mxi1 in mice led to the development of polycystic kidney disease (PKD) similar to the PKD observed in Tsc1-deficient mice (Schreiber-Agus et al., 1998) . Notably, Myc transgenic mice also developed PKD (Trudel et al., 1991) . These mouse genetic studies thus provide important complementary evidence to our computational and functional analyses in support of the critical function of Myc-Mxi1 signaling in mTORC1-FoxO-directed renal tumorigenesis.
Myc and Mxi1 are also highly relevant to human RCC. Recent oncogenomic profiles show that Myc is amplified in about 12% clear cell RCC samples and is the only gene in the 8q amplification peak region, confirming Myc as an oncogene in human kidney cancer (Beroukhim et al., 2009) . Furthermore, Mxi1 locus is subjected to homozygous and hemizygous deletion in a subset of clear cell RCC samples (Beroukhim et al., 2009) , suggesting that Mxi1 functions as a tumor suppressor in human kidney cancer. Mechanistically, it has been shown that Myc can crosstalk with HIF signaling to regulate cell cycle entry, metabolism, and mitochondrial biogenesis in RCC cells (Dang et al., 2008; Gordan et al., 2007a Gordan et al., , 2007b Zhang et al., 2007) . Further study will be necessary to investigate whether FoxO can regulate cancer cell metabolism and mitochondrial biogenesis in the context of renal tumorigenesis via Myc signaling.
Finally, our data also point to combination therapeutic regimens for improved treatment of renal cancer. Specifically, because our study demonstrated that FoxOs are extinguished in the majority of human RCC samples and serve as an critical tumor suppressor axis in renal cancer, it predicts that mTORC1 inhibition (or mTORC1/PI3K inhibition) would not affect the downstream oncogenic effect afforded by loss of FoxO, which explains, at least in part, why mTORC1 inhibition has relatively limited impact on kidney cancer patients. Our study further suggests combination therapy by mTORC1 inhibition and a FoxO restabilization/activation and/or Myc destabilization strategy might provide improved treatment in kidney cancer. As discussed above, currently we favor a model that FoxO extinction in human RCC might result from posttranslational mechanism (such as phosphorylation-mediated protein degradation). Further understanding of how FoxOs are extinguished in human RCC might therefore provide treatment strategies in RCC, including such strategies as blocking Crm1-mediated nuclear export. Alternatively, our study suggests that combined inhibition of mTORC1 and Myc signaling might further improve the treatment of kidney cancer. Interference of Myc signaling may be provided by current efforts to target Myc heterodimerization with Max or by targeting factors regulating Myc protein degradation.
In summary, this integrated genetic, transcriptomic, computational, and cell biological study has provided additional insights into the molecular basis of mTORC1-mediated negative feedback in the context of renal tumorigenesis. Our study identifies FoxO transcription factors as a critical checkpoint that functions to constrain mTORC1-mediated renal tumorigenesis and serves as a tumor suppressor axis in renal cancer. Further study of the FoxO network may illuminate additional points of therapeutic intervention and provide pharmacodynamic markers for guiding the development of agents targeting components of the PI3K pathway in RCC patients.
EXPERIMENTAL PROCEDURES Generation and Analysis of Mice
The Rosa26-CreERT2 mice (Vooijs et al., 2001) , Rosa26-CreERT2 mice, which were then crossed with Tsc1 L/L mice (Kwiatkowski et al., 2002) to generate various mice lines with desired genotypes. All cohorts were in a FVB/n, C57Bl/6, and 129/Sv mixed genetic background. Littermates at 4-5 weeks of age were treated daily by intraperitoneal injection of tamoxifen in corn oil (0.13 mg/g body weight) for 5 consecutive days (Gan et al., 2008) . The tamoxifen was intended to induce CreERT2 translocation into the nucleus, thereby leading to transient Cre-mediated recombination. Overall survival, as well as spontaneous formation of tumors, was monitored in various cohorts. Animals were autopsied and all tissues were examined regardless of their pathological status. All animal manipulations were performed with Harvard's and Dana-Farber Cancer Institute's Institutional Animal Care and Use Committee (IACUC) approval.
Human Samples
Human RCC TMA and RNA samples were obtained from Renal Cancer Tissue Acquisition, Pathology, and Clinical Data Core (TAPCD) at Dana-Farber/ Harvard Cancer Center (DF/HCC) Kidney Cancer SPORE directed by S.S. All patients provided informed consent and the study was approved by the Institutional Review Boards of Dana-Farber Cancer Institute and DF/HCC Renal Cancer TAPCD Core Utilization Committee (RCTUC).
Antibodies for Immunohistochemistry and Western Blot Analysis
The following antibodies were used: Vinculin (Sigma), Myc (sc-42, Santa Cruz, to detect endogenous Myc), Myc (9E10, Santa Cruz, to detect Myc tag), S6K (Santa Cruz), TSC1, FoxO1 (C29H4), FoxO3 (75D8), FoxO4, Thr24 phosphoFoxO1/Thr32 FoxO3, AKT, Ser473 phospho AKT, S6, Ser240/244 phospho-S6, Thr389 phospho-S6K, PARP, and cleaved-Caspase 3 (all from Cell Signaling Technology).
Constructs and Reagents
FoxO1(TA) and FoxO3(TA) cDNAs were obtained from addgene, and then were fused with Myc-tagged ERT2 at C terminus and cloned in retroviral vector pBabe. Myc expression construct is described in our recent publication (Zheng et al., 2008) . Lentiviral shRNA vectors targeting human Mxi1 and nontargeting control construct shGFP were obtained from the RNAi Consortium at the Dana-Farber/Broad Institute. Lentiviral mir-145 expression vector was purchased from System Biosciences. Anti-mir-145 and scrambled oligos were ordered from Exiqon.
Cell Culture Studies
Immortalized human kidney cells (HK2), human kidney cancer cell lines used in this study, and human embryonic kidney cell line HEK293T were purchased from American Type Culture Collection (ATCC). Lentiviruses or retroviruses were produced in HEK293T cells with packing mix (ViraPower Lentiviral Expression System, Invitrogen) and used to infect target cells as per manufacturer's instruction. To reactivate FoxO, FoxO1(TA)ERT2 or FoxO3(TA)ERT2 cells were treated with 100 nM 4OHT or vehicle for different periods of time as indicated and subjected to various analyses. Cell proliferation assays were performed in 12-well plates in triplicate with 10,000 cells per well. Cells were fixed in 10% formalin in PBS, and stained with crystal violet at different days as indicated. At the conclusion of the assay, crystal violet was extracted with 10% acetic acid and absorbance at 595 nm was measured with 96-well plate reader.
ChIP Analysis
Chip experiment was performed using EZ-Chip Kit (Chemicon) as per manufacturer's instruction.
Expression Profiling and Quantitative Real-Time PCR Analysis
Details of expression profiling and quantitative real-time PCR analysis are provided in Supplemental Experimental Procedures.
Statistical Analysis
Tumor-free survivals were analyzed using GraphPad Prism4. Statistical analyses were performed using nonparametric Mann-Whitney test. Comparisons of cell growth and gene expression were performed using the unpaired Student's t test. For all experiments with error bars, standard deviation was calculated to indicate the variation within each experiment and data, and values represent mean ± standard error of mean.
ACCESSION NUMBERS
Completed microarray data have been deposited in the Gene Expression Omnibus website with accession code GSE23926. 
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